These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 27671772)

  • 1. The renin-angiotensin-aldosterone system in heart failure for the non-specialist: the past, the present and the future.
    Orsborne C; Chaggar PS; Shaw SM; Williams SG
    Postgrad Med J; 2017 Jan; 93(1095):29-37. PubMed ID: 27671772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neprilysin Inhibitors in Cardiovascular Disease.
    Kang G; Banerjee D
    Curr Cardiol Rep; 2017 Feb; 19(2):16. PubMed ID: 28185171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renin-angiotensin-aldosterone system inhibitors in heart failure.
    Shearer F; Lang CC; Struthers AD
    Clin Pharmacol Ther; 2013 Oct; 94(4):459-67. PubMed ID: 23852393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meta-Analysis Evaluating the Effects of Renin-Angiotensin-Aldosterone System Blockade on Outcomes of Heart Failure With Preserved Ejection Fraction.
    Kuno T; Ueyama H; Fujisaki T; Briasouli A; Takagi H; Briasoulis A
    Am J Cardiol; 2020 Apr; 125(8):1187-1193. PubMed ID: 32081366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined angiotensin receptor/neprilysin inhibitors: a review of the new paradigm in the management of chronic heart failure.
    Macdonald PS
    Clin Ther; 2015 Oct; 37(10):2199-205. PubMed ID: 26386501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple renin-angiotensin-aldosterone-blocking agents in heart failure: how much is too much?
    Pitt B
    Curr Heart Fail Rep; 2009 Jun; 6(2):112-6. PubMed ID: 19486595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination Therapy of Renin Angiotensin System Inhibitors and β-Blockers in Patients with Heart Failure.
    Nochioka K; Sakata Y; Shimokawa H
    Adv Exp Med Biol; 2018; 1067():17-30. PubMed ID: 29542073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The renin-angiotensin-aldosterone system and heart failure.
    Sayer G; Bhat G
    Cardiol Clin; 2014 Feb; 32(1):21-32, vii. PubMed ID: 24286576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The path to an angiotensin receptor antagonist-neprilysin inhibitor in the treatment of heart failure.
    Braunwald E
    J Am Coll Cardiol; 2015 Mar; 65(10):1029-41. PubMed ID: 25766951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sex differences in heart failure medications targeting the renin-angiotensin-aldosterone system.
    Nicolaou PA
    Eur J Pharmacol; 2021 Apr; 897():173961. PubMed ID: 33617824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heart Failure Guidelines on Pharmacotherapy.
    Papadimitriou L; Hamo CE; Butler J
    Handb Exp Pharmacol; 2017; 243():109-129. PubMed ID: 28451824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time to retrieve the best benefits from renin angiotensin aldosterone system (RAAS) inhibition in heart failure patients with reduced ejection fraction: lessons from randomized controlled trials and registries.
    Rossignol P; Zannad F; Pitt B;
    Int J Cardiol; 2014 Dec; 177(3):731-3. PubMed ID: 25465821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin receptor neprilysin inhibitor LCZ696: pharmacology, pharmacokinetics and clinical development.
    Hua Y; Wang I; Liu B; Kelly DJ; Reid C; Liew D; Zhou Y; Wang BH
    Future Cardiol; 2017 Mar; 13(2):103-115. PubMed ID: 27892684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Focused Treatment of Heart Failure with Reduced Ejection Fraction Using Sacubitril/Valsartan.
    Liu RC
    Am J Cardiovasc Drugs; 2018 Dec; 18(6):473-482. PubMed ID: 29850980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
    Hubers SA; Brown NJ
    Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual Angiotensin Receptor and Neprilysin Inhibition with Sacubitril/Valsartan in Chronic Systolic Heart Failure: Understanding the New PARADIGM.
    Lillyblad MP
    Ann Pharmacother; 2015 Nov; 49(11):1237-51. PubMed ID: 26175499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances.
    McMurray JJ
    Eur J Heart Fail; 2015 Mar; 17(3):242-7. PubMed ID: 25756942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LCZ696 (angiotensin-neprilysin inhibition): the new kid on the heart failure block?
    Pham AQ; Patel Y; Gallagher B
    J Pharm Pract; 2015 Apr; 28(2):137-45. PubMed ID: 25864789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renin-angiotensin-aldosterone system blockers for heart failure with reduced ejection fraction or left ventricular dysfunction: Network meta-analysis.
    Xie W; Zheng F; Song X; Zhong B; Yan L
    Int J Cardiol; 2016 Feb; 205():65-71. PubMed ID: 26720043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and outcomes associated with early heart failure pharmacotherapy in patients with ongoing cardiogenic shock.
    van Diepen S; Reynolds HR; Stebbins A; Lopes RD; Džavík V; Ruzyllo W; Geppert A; Widimsky P; Ohman EM; Parrillo JE; Dauerman HL; Baran DA; Hochman JS; Alexander JH
    Crit Care Med; 2014 Feb; 42(2):281-8. PubMed ID: 23982033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.